Introduction
Two types of reactive oxygen species (ROS), nitric oxide (NO K ) and superoxide ( K O 2 -), are critically involved in persistent pain [1] . It has been shown that NO K is produced in the spinal dorsal horn neurons in response to extensive nociceptive inputs. Then, it diffuses out and increases neurotransmitter release from primary afferent terminals, thereby contributing to central sensitization and persistent pain [2, 3] . In contrast, recent studies have shown that reducing spinal K O 2 levels decreases central sensitization and hyperalgesia [4, 5] , thus indicating that K O 2 also plays a critical role in persistent pain. K O 2 is known to activate various kinases, including protein kinase C (PKC) [6] , which is critical for sensitization of spinal neurons and persistent pain [4, 5, 7] . In addition, it also seems possible that K O 2 and NO K can be generated simultaneously and react with each other to produce highly toxic peroxynitrite (ONOO -). Therefore, ONOOhas been proposed as a converged downstream molecule of K O 2 and NO K in persistent pain conditions [8] . However, the relationships among K O 2 -, NO K , and ONOOin pain signaling pathways are not clear. This study is thus conducted to determine whether K O 2 and NO K induce pain through independent pain pathways or use ONOOas a common mechanism.
Methods

Animals
Adult wild-type male C57 BL/6J mice (8-10 weeks old) were purchased from Jackson Laboratory (Bar Harbor, Maine, USA). All animal procedures were performed in accordance with the animal protocol approved by the Institutional Animal Care and Use Committee at the University of Texas Medical Branch. All behavioral experiments were conducted blindly with respect to the drug administration.
Preparation of animal models Neuropathic pain model
Peripheral neuropathy was produced by a unilateral L5 spinal nerve ligation [9] . Briefly, under isoflurane anesthesia, the left L5 spinal nerve was isolated and tightly ligated with 7-0 silk thread. Mechanical sensitivity was assessed before and 7 days after ligation.
Nitric oxide-induced hyperalgesia
A NO K -releasing compound, NOC12, was intrathecally (i.t.) injected to produce NO K -induced hyperalgesia [10] . An optimal i.t. dose of NOC12 (3 mg in 5 ml saline) for each mouse was determined by a preliminary study, based on an earlier rat study [10] . Mechanical sensitivity was assessed before and at various times after NOC12 injection.
Superoxide-induced hyperalgesia
Recently, we introduced an K O 2 --induced hyperalgesia model [11] using a mitochondrial electron transport complex inhibitor. Briefly, stock solution (1 mM) of antimycin A (complex III inhibitor; mitochondrial K O 2 generator) was prepared in absolute ethanol and diluted in saline just before each experiment. Antimycin A (0.137 mg in 5 ml of 5% ethanol-saline) was injected i.t. in normal mice. Mechanical sensitivity was assessed before and from 9 h after antimycin A injection.
Behavioral testing
Mechanical sensitivity was assessed by measuring foot withdrawal frequencies in response to von Frey stimuli (von Frey number 3.61, 0.41 gram force; Stoelting Co., Wood Dale, Illinois, USA) [11] . The animal was placed in a plastic chamber on top of a mesh screen platform. The von Frey filament was applied perpendicularly to the base of the fourth toe of neuropathic mice (one area; ipsilateral paw to surgery) and the base of the fourth toe and midplantar region (four areas; both paws) for antimycininduced or NOC12-induced hyperalgesia. Ten stimuli were applied to each area at a 10-20 s interval. An abrupt withdrawal with or without licking of the foot, during stimulation or immediately after stimulus removal, was considered a positive response. Foot withdrawal frequency was quantified as = (total number of positive foot withdrawals/total stimuli)Â 100. The mechanical sensitivity was assessed before (0) and 20, 40, 60, 90, and 120 min after i.t. injection of test compounds.
Drugs and intrathecal administration
The tested drugs and their i.t. doses were: a ROS scavenger, phenyl N-tert-butylnitrone (100 mg), a K O 2 scavenger, 4-hydroxy-2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPOL; 100 mg), a NO synthase inhibitor, N G -nitro-L-arginine methyl ester (L-NAME; 100 mg), an ONOOdecomposition catalyst, 5,10,15,20-tetrakis (N-methyl-4pyridyl) porphyrinato iron III (FeTMPyP; 1 mg), a PKC inhibitor, GF109203X (1.6 pg), and a guanyl cyclase inhibitor, methylene blue (MB; 5 mg; Harleco, Gibbstown, New Jersey, USA). All chemicals except MB were purchased from Sigma Chemical (St. Louis, Missouri, USA). All drugs were dissolved in 0.9% saline (except GF109203X) and administered i.t. in a volume of 5 ml. GF109203X was stored in 100% dimethyl sulfoxide at a concentration of 4.5 Â10 5 pg/ml and diluted with saline to the proper concentration immediately before use. The above i.t. doses, except FeTMPyP, are based on earlier reports [8, 12] . For i.t. FeTMPyP, the maximum tolerable dose 1 mg, which showed no abnormal behaviors, such as paralysis, itching, and tail biting, was determined from our preliminary study and was used in this study. All mice were injected by a modified direct transcutaneous i.t. method using a disposable 30-gauge needle [13] . Vehicle groups received the same volume of saline or vehicle (0.00007% dimethyl sulfoxide in saline; for the vehicle control group of GF109203X experiment).
Nitrotyrosine immunohistochemistry
Seven days after spinal nerve ligation surgery, the L4-L5 spinal cord segments were removed, post-fixed for 4 h, cryoprotected in 30% sucrose, and cryosectioned at 10 mm in thickness and mounted on gelatin coated slides. The sections were incubated with anti-nitrotyrosine (an ONOOmarker; 1 : 100; Sigma Chemical) and anti-NeuN (a neuronal marker; 1 : 2000; Chemicon, Billerica, Massachusetts, USA), followed by secondary antibodies conjugated with fluorescent dyes, Alexa Fluor 568 (red; Invitrogen, Eugene, Oregon, USA) and 488 (green; Invitrogen), respectively. A positive control for nitrotyrosine immunostaining was prepared by adding 110 mM ONOO -(Upstate, Temecula, California, USA) to cord sections of normal mice. Spinal dorsal horn was examined and photographed with a Â40 objective on a laserscanning confocal microscope (Olympus, Center Valley, Pennsylvania, USA).
Data analysis
Data are presented as mean ± SEM and analyzed by one-way or two-way repeated-measurement analysis of variance, followed by post-hoc testing using the Holm-Sidak method. P values r 0.05 were considered statistically significant.
Results
Both superoxide and nitric oxide are involved in generation of neuropathic pain
In the neuropathic mice, i.t. injection of either an K O 2 scavenger, TEMPOL, or a nonselective NO K synthase inhibitor, L-NAME, greatly reduced mechanical hyperalgesia. This significant antihyperalgesic effect peaked at 20 min and lasted up to 40 min after injection, compared with the vehicle group. An ONOOdecomposition catalyst, FeTMPyP, however, did not reduce mechanical hyperalgesia ( Fig. 1a and b) . The nitrotyrosine immunostaining, an indicator of the presence of ONOO -, was not detected in the spinal cord of neuropathic mice (Fig. 1d) .
The results indicate that NO K and K O 2 -, but not ONOO -, are critical contributors for neuropathic pain.
Spinal nitric oxide-induced foot hyperalgesia is independent of superoxide action As i.t. FeTMPyP failed to reverse mechanical hyperalgesia in neuropathic mice, we speculated that K O 2 and NO K might act independently in pain generation without converging to ONOO -. First, we tested whether NO K could generate pain without any interaction with endogenous K O 2 - (Fig. 2a ). Intrathecal injection of NOC12, a NO K -releasing compound, induced hyperalgesia on the hind paw in normal mice. The NO K -induced hyperalgesia was inhibited by i.t. coadministration of a general ROS scavenger, phenyl N-tert-butylnitrone, or a guanyl cyclase inhibitor, MB, but not by an K O 2 scavenger, TEMPOL (Fig. 2b) . The data suggest that spinal NO K may induce hyperalgesia through the NO Kcyclic guanosine monophosphate (cGMP) pathway without involvement of K O 2 -.
Spinal superoxide-induced foot hyperalgesia is independent of nitric oxide action
In the next experiment, we tested whether endogenous NO K was involved in the spinal K O 2 --induced foot pain model (Fig. 2c ). Intrathecal injection of antimycin A, an K O 2 generator, produced hyperalgesia on the hind foot.
This K O 2 --induced hyperalgesia was inhibited by a K O 2 scavenger, TEMPOL, and by a PKC inhibitor, GF 109203X, but not by an NO K synthase inhibitor, L-NAME (Fig. 2d) . The data indicate that spinal K O 2 can contribute to pain through the K O 2 --PKC pathway, without any interaction with endogenous NO K .
Discussion
Highly toxic ONOO -, the reaction product of NO K and K O 2 -, has been proposed as the culprit for persistent pain [8, 14] . This is based on indirect evidence that: (i) theoretically, NO K and K O 2 rapidly combine to yield ONOO -, six times faster than the removal of K O 2 by [15] ; and (ii) inhibition of NO K or K O 2 with L-NAME or TEMPOL, respectively, produces analgesia in rodent neuropathic pain models [8, 14] . Consistent with the earlier reports [1, 8] , TEMPOL and L-NAME produced potent analgesic effects in neuropathic mice in this study, thus confirming that both K O 2 -and NO K critically contribute to neuropathic pain. The lack of antihyperalgesic effect of FeTMPyP and nitrotyrosine immunostaining in the neuropathic mice, however, suggests that NO K and K O 2 may operate through two independent pathways, without converging to ONOOformation. This point is further confirmed by showing that NO K -induced and K O 2 --induced hyperalgesia is mediated through the cGMP and PKC signaling pathways, respectively, without the presence of the other ROS in the system. In addition to having independent signaling pathways, NO K and K O 2 seem to function at different sites. NO K is well known as a retrograde messenger because it is produced in the postsynaptic neuron but diffuse back to presynaptic terminals and potentiate glutamate release through modulation of the cGMP [16, 17] . In contrast, K O 2 seems to be produced in and sensitizes the spinal dorsal horn neurons, thus mainly functioning through postsynaptic mechanisms. The fact that TEMPOL suppresses only the central sensitization [4, 5, 7, 13] support postsynaptic action of K O 2 -. Thus, it may be reasonable to note that K O 2 and NO K function independently at postsynaptic and presynaptic sites, respectively, while both contributing to the same persistent pain.
ONOOdecomposition catalysts rapidly convert ONOOto relatively harmless nitrate, thus reducing the formation of cytotoxic hydroxyl radicals and protein nitration [15] . A ONOOdecomposition catalyst, FeTMPyP, exhibits good specificity for ONOO -, and does not affect NO K and K O 2 action. Moreover, it catalyzes ONOOmost rapidly among the iron-based catalysts [18] and almost exclusively to harmless nitrate [19] . Despite rapid, specific ONOO-scavenging properties of FeTMPyP, a single injection of FeTMPyP, did not affect mechanical hyperalgesia in neuropathic mice. In our preliminary study (n = 5), a high dose of FeTMPyP (10 mg in 5 ml, i.t.) produced paralysis (n = 2) and moderate doses (2 or 5 mg in 5 ml, i.t.) did not affect neuropathic pain, while producing a transient paralysis in some mice (n = 3). In contrast to our results, FeTMPyP has been shown to inhibit hyperalgesia or partially restore defective autonomic function in diabetic mice [20, 21] . As the FeTMPyP effect in the diabetic neuropathy has been observed after repeated, long-term systemic treatments (over 2 weeks) with a high dose, it is likely that ONOOinvolvement in persistent pain is indirect because it induces slow cumulative cell damage [15] .
In conclusion, our study suggests that NO K and K O 2 contribute to persistent pain through two separate and independent pathways. 
